表紙
市場調查報告書

眼科用醫藥品受託製造市場:API、FDF

Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030

出版商 ROOTS ANALYSIS 商品編碼 920001
出版日期 內容資訊 英文 473 Pages
商品交期: 最快1-2個工作天內
價格
眼科用醫藥品受託製造市場:API、FDF Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030
出版日期: 2020年01月31日內容資訊: 英文 473 Pages
簡介

本報告提供眼科用醫藥品受託製造市場相關調查分析,以眼科用產品、解決方案的受託服務市場為對象,目前的市場情勢和未來預測相關的系統性資訊。

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 目前的市場情勢

  • 概要
  • 眼科用醫藥品受託廠商:整體市場形勢

第5章 企業的競爭分析

  • 概要
  • 主要的前提條件、手法
  • 競爭分析:眼科用API受託廠商
  • 競爭分析:眼科用醫藥品FDF受託廠商

第6章 北美眼科用醫藥品受託製造:企業簡介

  • 概要
  • Akorn
  • Catalent
  • Cayman Chemical
  • Pillar5 Pharma
  • Sterling Pharmaceutical Services

第7章 歐洲的眼科用醫藥品受託製造:企業簡介

  • 概要
  • FARMIGEA
  • Lomapharm
  • Medichem
  • Recipharm
  • Salvat

第8章 亞太地區眼科用醫藥品受託製造:企業簡介

  • 概要
  • Akums
  • Bal Pharma
  • Entod Pharmaceuticals
  • Glenmark Pharmaceuticals
  • Indiana Ophthalmics
  • Sunways India

第9章 臨床試驗分析

  • 概要
  • 範圍、手法
  • 眼科用醫藥品實驗分析

第10章 生產能力分析

  • 概要
  • 主要的前提條件、手法
  • 眼科用API受託廠商:全球生產能力 (各數量)
  • 眼科用醫藥品FDF受託廠商:全球生產能力

第11章 需求分析

  • 概要
  • 主要的前提條件、手法
  • 對眼科用醫藥品受託製造的全球性的商用需求
  • 對眼科用醫藥品受託製造的全球性的臨床需求
  • 需求與供給分析

第12章 市場預測

  • 概要
  • 主要的前提條件、手法
  • 眼科用醫藥品受託製造市場全體
  • 眼科用醫藥品受託製造市場:各產品類型的分佈
  • 眼科用醫藥品受託製造市場:各標的疾病適應症的分佈
  • 眼科用醫藥品受託製造市場:各經營規模的分佈
  • 眼科用醫藥品受託製造市場:各廠商規模的分佈
  • 眼科用醫藥品受託製造市場:各地區的分佈

第13章 案例研究:低分子、高分子的眼科用醫藥品/治療比較

第14章 SWOT分析

第15章 調查分析

第16章 執行考察

第17章 未來的成長機會

第18章 附錄 1:眼科用醫療設備受託製造商清單

第19章 附錄 2:圖表

第20章 附錄 3:企業、組織的清單

目錄

Example Insights:

In order to acquire ompetencies across the supply chain and cater to evolving needs of sponsors, companies have established presence across different regions, having been certified by various regulatory authorities.

Overview:

Ophthalmic diseases, such as age-related macular degeneration, cataract, diabetic retinopathy, dry eye and glaucoma, are considered among the leading causes of vision loss across the globe. According to the World Health Organization's report published in 2019, at least 2.2 billion individuals in the world are reported to be visually impaired. In fact, blindness caused due to multiple reasons, is projected to increase to 75 million affected individuals by 2020. Moreover, current estimates indicate that the total economic burden related to vision loss is expected to reach approximately USD 384 billion by 2030, in the US alone. The rise in incidence and prevalence of chronic eye disorders has prompted the medical research community to actively develop a variety of ophthalmic drugs / therapies. The current ophthalmic diseases treatment landscape is characterized by a number of blockbuster therapies, namely ALPHAGAN®, COSOPT®, LUMIGAN®, PAZEO®, RESTASIS®, TRAVATAN Z®, and XALATAN®, and a robust pipeline of over 400 candidate drugs in various stages of clinical development, designed for the treatment of approximately 1,000 chronic eye disorders.

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers. Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are known to offer significant benefits, which include reduction in capital investment, access to larger production capacities, reductions in time-to-market and also guarantee a significant degree of commercial risk mitigation. Since 2000, more than 75 new ophthalmology focused CMOs have been established. Amidst the tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry. This has caused many service providers to actively expand their respective service portfolios, either through strategic acquisitions or facility / capability expansions. Over time, many CMOs / CDMOs claim to have developed end-to-end service capabilities, ranging from drug development (including preliminary R&D, preclinical studies and clinical trials), to regulatory filings, and commercial scale production.

Scope of the Report:

The ‘Ophthalmic Drugs Contract Manufacturing Market, 2020-2030' report features an extensive study of the contract services market for ophthalmic products and solutions. It is worth mentioning that the study primarily focuses on small molecule active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), including ophthalmic drops, emulsions, gels, injections, lotions, ointments, suspensions, and tablets / capsules. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. Amongst other elements, the report includes:

  • A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, scale of operation (preclinical, pilot, clinical, and commercial), type of product (APIs and FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and injectables), type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, sachets / pouches, blister packing, and other forms), type of service(s) offered (pre-formulation, drug formulation, method validation, process development, analytical testing, stability studies, technology transfer, scale-up, fill / finish, and regulatory support), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.
  • A company competitiveness analysis, highlighting prominent ophthalmic drug contract manufacturers based on supplier strength (which was calculated considering the size of employee base of a company and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities, and number of regulatory accreditations / certifications).
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific that offer a diverse range of capabilities for the development, manufacturing and packaging of ophthalmic drug products. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.
  • A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products, highlighting prevalent trends across parameters, such as current trial status, trial registration year, enrolled patient population and trial location, phase of development, study design, leading industry and non-industry players (in terms of number of trials undertaken / conducted), study focus, and key disease indications (in terms of number of trials undertaken / conducted).
  • An informed estimate of the annual commercial demand for ophthalmic APIs and drug FDFs (in million litres), taking into account the top 30 small molecule-based ophthalmic drugs; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for ophthalmic drug products was also estimated, taking into account ongoing and planned clinical trials.
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market, based on data gathered via secondary and primary research. It also provides the likely distribution of the global ophthalmic product-related manufacturing capacity available across different types of companies (small-sized, mid-sized, and large-sized), scales of operation (preclinical, clinical and commercial), types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and ointment tubes), and key geographical regions (North America, Europe, and Asia-Pacific).
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to ophthalmic drug developers.
  • A discussion on the emerging trends and potential market drivers, such as the growing ophthalmic drugs / therapies pipeline, rise in outsourcing activity for sterile manufacturing operations, adoption of innovative technologies and increasing opportunities in the Asia-Pacific region, which are likely to impact the evolution of the market in the coming years.
  • A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on year of establishment, company size, geographical location, key application area(s) (diagnostics, drug delivery, therapeutics, and others), type of manufacturing service(s) offered (design, component manufacturing, assembly, prototype development, sterilization, quality assurance, and packaging), type of additional service(s) offered (consultancy, documentation, inspection / testing, labelling, logistics, project management, regulatory support, repair, warehouse / storage, and others), scale of operation (pilot and commercial), device class-related expertise (class I, class II and class III), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as growth of the overall ophthalmic drugs market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of product (APIs and FDFs), [B] type of FDF manufactured (solids, semi-solids, and liquids / suspensions), [C] type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, blister packing, and other forms), [D] scale of manufacturing (preclinical, clinical, and commercial), [E] company size (small sized, mid-sized, and large-sized companies), [F] key disease indications (age-related macular degeneration, glaucoma, uveitis, dry eye, and other disease segments), and [G] key geographical regions, covering North America (the US, Canada and Mexico), Europe (the UK, Germany, France, Spain, Italy and rest of Europe), and Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific). To account for the uncertainties associated with the growth of the ophthalmic drugs contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions presented in this study were influenced by inputs (through an industry-wide survey) of several key players in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals:

  • Rahul Gupta (Chief Executive Officer, Selvok Pharmaceutical)
  • Vivek Partheeban (Chief Operating Officer, Caplin Point Laboratories) and Ashok Partheeban (Director, Latin American Operations, Caplin Point Laboratories)
  • Stuart Smith (Managing Director, Phytex Australia)
  • Iranna Bavalatti (General Manager, Gland Pharma)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the ophthalmic drugs contract manufacturing market in the mid to long term.

Chapter 3 presents a general overview of the field of ophthalmology, including information on various chronic eye disorder and the economic burden associated with such conditions. Further, it features a detailed discussion on a variety of ophthalmic drug formulations and affiliated primary packaging. It also provides inputs on the various benefits and challenges associated with the aforementioned products across different types of ophthalmic diseases. Further, the chapter features a brief overview of contract manufacturing and a discussion on the need for outsourcing within the ophthalmic drugs market. In addition, it includes a list of commonly outsourced aseptic manufacturing services and highlights the key factors that need to be considered during the selection of potential CMOs, along with information on key challenges that are currently associated within this market. The chapter concludes with a discussion on the key growth drivers and roadblocks related to ophthalmic drugs contract manufacturing, as well as upcoming trends that the field is expected to witness in the coming years.

Chapter 4 provides a comprehensive overview on the global ophthalmic drugs contract manufacturing landscape. It includes information related to over 240 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market based on a number of parameters, such as year of establishment, company size, geographical location, scale of operation (preclinical, pilot, clinical, and commercial), type of product (APIs and FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and injectables), type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, sachets / pouches, blister packing, and other forms), type of service(s) offered (pre-formulation, drug formulation, method validation, process development, analytical testing, stability studies, technology transfer, scale-up, fill / finish, and regulatory support), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.

Chapter 5 features an insightful company competitiveness analysis of both ophthalmic API and drug FDF contract manufacturers based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each business operation and geography on the basis of supplier strength (which was calculated considering the size of employee base of a company and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities, and number of regulatory accreditations / certifications).

Chapter 6 includes detailed profiles of some of the key players that are active in the ophthalmic drugs contract manufacturing market in North America. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.

Chapter 7 includes detailed profiles of some of the key players that are active in the ophthalmic drugs contract manufacturing market in Europe. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.

Chapter 8 includes detailed profiles of some of the key players that are active in the ophthalmic drugs contract manufacturing market in Asia-Pacific. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.

Chapter 9 provides a comprehensive clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and trial location, phase of development, study design, leading industry and non-industry players (in terms of number of trials undertaken / conducted), study focus, and key disease indications (in terms of number of trials undertaken / conducted).

Chapter 10 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of ophthalmic drug products. The analysis takes into consideration the individual manufacturing capacities of various stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market, using data from both secondary and primary research. It also examines the likely distribution of the global ophthalmic product-related manufacturing capacity available across different types of companies (small-sized, mid-sized, and large-sized), scales of operation (preclinical, clinical and commercial), types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and ointment tubes), and key geographical regions (North America, Europe, and Asia-Pacific).

Chapter 11 features a detailed estimate of the annual demand for ophthalmic APIs and drug FDFs (in million liters), offering an informed opinion on the required scale of supply (in terms of ophthalmic drug contract manufacturing services). In order to estimate the annual commercial demand, we considered the top 30 small molecule-based ophthalmic drugs; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for ophthalmic drug products was also estimated, taking into account the ongoing and planned clinical trials.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the ophthalmic drugs contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of product (APIs and FDFs), [B] type of FDF manufactured (solids, semi-solids, and liquids / suspensions), [C] type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, blister packing, and other forms), [D] scale of manufacturing (preclinical / clinical and commercial), [E] company size (small sized, mid-sized, and large-sized companies), [F] key disease indications (age-related macular degeneration, glaucoma, uveitis, dry eye, and other disease segments), and [G] key geographical regions, covering North America (the US, Canada and Mexico), Europe (the UK, Germany, France, Spain, Italy and rest of Europe), and Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific).

Chapter 13 is a case study comparing the key characteristics of large and small molecule ophthalmic drugs, along with information on the steps involved in their respective manufacturing processes.

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of ophthalmic drugs contract manufacturing market, under a comprehensive SWOT framework.

Chapter 15 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the ophthalmic drugs contract manufacturing market.

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Rahul Gupta (Chief Executive Officer, Selvok Pharmaceutical), Vivek Partheeban (Chief Operating Officer, Caplin Point Laboratories) and Ashok Partheeban (Director, Latin American Operations, Caplin Point Laboratories), Stuart Smith (Managing Director, Phytex Australia), and Iranna Bavalatti (General Manager, Gland Pharma).

Chapter 17 highlights the emerging trends and potential market drivers for ophthalmic drug contract manufacturers. It highlights the various opportunities associated with the growing ophthalmic drugs / therapies pipeline, increase in outsourcing of aseptic manufacturing operations, adoption of innovative technologies and increasing opportunities in the Asia-Pacific region, which are likely to impact the evolution of the market in the coming years.

Chapter 18 is an appendix, which provides a comprehensive list of over 55 ophthalmic medical device contract manufacturers, along with information on year of establishment, company size, geographical location, key application area(s) (diagnostics, drug delivery, therapeutics, and others), type of manufacturing service(s) offered (design, component manufacturing, assembly, prototype development, sterilization, quality assurance, and packaging), type of additional service(s) offered (consultancy, documentation, inspection / testing, labelling, logistics, project management, regulatory support, repair, warehouse / storage, and others), scale of operation (pilot and commercial), device class-related expertise (class I, class II and class III), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix, which provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Introduction to Ophthalmology
    • 3.2.1. Anatomy of the Human Eye
    • 3.2.2. Chronic Eye Conditions and Associated Economic Burden
  • 3.3. Common Ophthalmic Drug Dosage Forms
    • 3.3.1. Types of Oral Drug Formulations
      • 3.3.1.1. Tablets
      • 3.3.1.2. Capsules
      • 3.3.1.3. Eye Supplements
    • 3.3.2. Types of Semi-solid Formulations
      • 3.3.2.1. Ointments
      • 3.5.2.2. Gels
      • 3.5.2.3. Emulsions
    • 3.3.3. Types of Liquid Drug Formulations
      • 3.3.3.1. Solutions
      • 3.3.3.2. Suspensions
      • 3.5.3.1. Sterile Injectables
    • 3.3.4. Intraocular Inserts
  • 3.4. Common Primary Packaging Formats for Ophthalmic Drugs
  • 3.5. Overview of Contract Manufacturing
  • 3.6. Outsourcing in the Ophthalmology Industry
    • 3.6.1. Need for Outsourcing
    • 3.6.2. Commonly Outsourced Operations
    • 3.6.3. Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner
    • 3.6.4. Advantages of Outsourcing Manufacturing Operations
    • 3.6.5. Challenges Associated with Ophthalmic Drugs Contract Manufacturing
    • 3.6.6. Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing
    • 3.6.7. Recent Developments and Upcoming Trends

4. CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Ophthalmic Drug Contract Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Scale of Operation
    • 4.2.4. Analysis by Geographical Location
    • 4.2.5. Analysis by Location of Manufacturing Facilities
    • 4.2.6. Analysis by Type of Product
    • 4.2.7. Analysis by Type of FDF Manufactured
    • 4.2.8. Analysis by Type of Primary Packaging
    • 4.2.9. Analysis by Type of Service(s) Offered
    • 4.2.10. Analysis by Regulatory Accreditations / Certifications

5. COMPANY COMPETITVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Key Assumptions and Methodology
  • 5.3. Competitiveness Analysis: Ophthalmic API Contract Manufacturers
    • 5.3.1. Ophthalmic API Contract Manufacturers in North America
    • 5.3.2. Ophthalmic API Contract Manufacturers in Europe
    • 5.3.3. Ophthalmic API Contract Manufacturers in Asia-Pacific
  • 5.4. Competitiveness Analysis: Ophthalmic Drug FDF Contract Manufacturers
    • 5.4.1. Ophthalmic Drug FDF Contract Manufacturers in North America
    • 5.4.2. Ophthalmic Drug FDF Contract Manufacturers in Europe
    • 5.4.3. Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific

6. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN NORTH AMERICA: COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Akorn
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Service Portfolio
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. Catalent
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Service Portfolio
    • 6.2.4. Recent Developments and Future Outlook
  • 6.4. Cayman Chemical
    • 6.4.1. Company Overview
    • 6.4.2. Service Portfolio
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. Pillar5 Pharma
    • 6.5.1. Company Overview
    • 6.5.2. Service Portfolio
    • 6.5.3. Recent Developments and Future Outlook
  • 6.6. Sterling Pharmaceutical Services
    • 6.6.1. Company Overview
    • 6.6.2. Service Portfolio
    • 6.6.3. Recent Developments and Future Outlook

7. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN EUROPE: COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. FARMIGEA
    • 7.2.1. Company Overview
    • 7.2.2. Service Portfolio
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. Lomapharm
    • 7.3.1. Company Overview
    • 7.3.2. Service Portfolio
    • 7.3.3 Recent Developments and Future Outlook
  • 7.4. Medichem
    • 7.4.1. Company Overview
    • 7.4.2. Service Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. Recipharm
    • 7.5.1. Company Overview
    • 7.5.2. Financial Information
    • 7.5.3. Service Portfolio
    • 7.5.4. Recent Developments and Future Outlook
  • 7.6. Salvat
    • 7.6.1. Company Overview
    • 7.6.2 Service Portfolio
    • 7.6.3. Recent Developments and Future Outlook

8. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN ASIA-PACIFIC: COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Akums
    • 8.2.1. Company Overview
    • 8.2.2. Service Portfolio
    • 8.2.3. Recent Developments and Future Outlook
  • 8.3. Bal Pharma
    • 8.3.1. Company Overview
    • 8.3.2. Financial Information
    • 8.3.3. Service Portfolio
    • 8.2.4. Recent Developments and Future Outlook
  • 8.4. Entod Pharmaceuticals
    • 8.4.1. Company Overview
    • 8.4.2. Service Portfolio
    • 8.4.3. Recent Developments and Future Outlook
  • 8.5. Glenmark Pharmaceuticals
    • 8.5.1. Company Overview
    • 8.5.2. Service Portfolio
    • 8.5.3. Recent Developments and Future Outlook
  • 8.6. Indiana Ophthalmics
    • 8.6.1. Company Overview
    • 8.6.2. Service Portfolio
    • 8.6.3. Recent Developments and Future Outlook
  • 8.7. Sunways India
    • 8.7.1. Company Overview
    • 8.7.2. Service Portfolio
    • 8.7.3. Recent Developments and Future Outlook

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Ophthalmic Drug Trial Analysis
    • 9.3.1. Analysis by Trial Registration Year
    • 9.3.2. Geographical Analysis by Number of Clinical Trials
    • 9.3.3. Geographical Analysis by Enrolled Patient Population
    • 9.3.4. Analysis by Phase of Development
    • 9.3.5. Analysis by Trial Recruitment Status
    • 9.3.6. Analysis by Type of Sponsor / Collaborator
    • 9.3.7. Most Active Players in Terms of Number of Registered Trials
    • 9.3.8. Analysis by Type of Intervention
    • 9.3.9. Analysis by Trial Focus
    • 9.3.10. Analysis by Target Indication
    • 9.3.11. Benchmark Analysis of Active Industry Players

10. CAPACITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Key Assumptions and Methodology
  • 10.3. Ophthalmic API Contract Manufacturers: Global Production Capacity (by Volume)
    • 10.3.1. Analysis by Geography
      • 10.3.1.1. Overall Production Capacity in North America (by Volume)
      • 10.3.1.2. Overall Production Capacity in Europe (by Volume)
      • 10.3.1.3. Overall Production Capacity in Asia-Pacific (by Volume)
    • 10.3.2. Analysis by Scale of Operation
      • 10.3.2.1. Overall Lab Scale Production Capacity (by Volume)
      • 10.3.2.2. Overall Clinical Scale Production Capacity (by Volume)
      • 10.3.2.3. Overall Commercial Scale Production Capacity (by Volume)
    • 10.3.3. Analysis by Company Size
      • 10.3.3.1. Overall Production Capacity of Small-sized Companies (by Volume)
      • 10.3.3.2. Overall Production Capacity of Mid-sized Companies (by Volume)
      • 10.3.3.3. Overall Production Capacity of Large-sized Companies (by Volume)
  • 10.4. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity
    • 10.4.1. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity (by Volume)
      • 10.4.1.1. Analysis by Geography
        • 10.4.1.1.1. Overall Production Capacity in North America (by Volume)
        • 10.4.1.1.2. Overall Production Capacity in Europe (by Volume)
        • 10.4.1.1.3. Overall Production Capacity in Asia-Pacific (by Volume)
      • 10.4.1.2. Analysis by Scale of Operation
        • 10.4.1.2.1. Overall Lab Scale Production Capacity (by Volume)
        • 10.4.1.2.2. Overall Clinical Scale Production Capacity (by Volume)
        • 10.4.1.2.3. Overall Commercial Scale Production Capacity (by Volume)
      • 10.4.1.3. Analysis by Company Size
        • 10.4.1.3.1. Overall Production Capacity of Small-sized Companies (by Volume)
        • 10.4.1.3.2. Overall Production Capacity of Mid-sized Companies (by Volume)
        • 10.4.1.3.3. Overall Production Capacity of Large-sized Companies (by Volume)
      • 10.4.1.4. Analysis by Type of Primary Packaging
        • 10.4.1.4.1. Overall Production Capacity of Ampoules / Vials (by Volume)
        • 10.4.1.4.2. Overall Production Capacity of Glass / Plastic Bottles (by Volume)
        • 10.4.1.4.3. Overall Production Capacity of Ointment Tubes (by Volume)
    • 10.4.2. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity (by Number of Units)
      • 10.4.2.1. Analysis by Geography
        • 10.4.2.1.1. Overall Production Capacity in North America (by Number of Units)
        • 10.4.2.1.2. Overall Production Capacity in Europe (by Number of Units)
        • 10.4.2.1.3. Overall Production Capacity in Asia-Pacific (by Number of Units)
      • 10.4.2.2. Analysis by Scale of Operation
        • 10.4.2.2.1. Overall Lab Scale Production Capacity (by Number of Units)
        • 10.4.2.2.2. Overall Clinical Scale Production Capacity (by Number of Units)
        • 10.4.2.2.3. Overall Commercial Scale Production Capacity (by Number of Units)
      • 10.4.2.3. Analysis by Company Size
        • 10.4.2.3.1. Overall Production Capacity of Small-sized Companies (by Number of Units)
        • 10.4.2.3.2. Overall Production Capacity of Mid-sized Companies (by Number of Units)
        • 10.4.2.3.3. Overall Production Capacity of Large-sized Companies (by Number of Units)
      • 10.4.2.4. Analysis by Type of Primary Packaging
        • 10.4.2.4.1. Overall Production Capacity of Ampoules / Vials (by Number of Units)
        • 10.4.2.4.2. Overall Production Capacity of Glass / Plastic Bottles (by Number of Units)
        • 10.4.2.4.3. Overall Production Capacity of Ointment Tubes (by Number of Units)

11. DEMAND ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. Global Commercial Demand for Ophthalmic Drugs Contract Manufacturing
    • 11.3.1. Commercial Demand for Ophthalmic API Contract Manufacturing
      • 11.3.1.1. Analysis by Geography
      • 11.3.1.2. Analysis by Scale of Operation
      • 11.3.1.3. Analysis by Target Indication
    • 11.3.2. Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing
      • 11.3.2.1. Analysis by Geography
      • 11.3.2.2. Analysis by Scale of Operation
      • 11.3.2.3. Analysis by Target Indication
      • 11.3.2.4. Analysis by Type of Primary Packaging
  • 11.4. Global Clinical Demand for Ophthalmic Drugs Contract Manufacturing
    • 11.4.1. Clinical Demand for Ophthalmic API Contract Manufacturing
      • 11.4.1.1. Analysis by Geography
      • 11.4.1.2. Analysis by Scale of Operation
      • 11.4.1.3. Analysis by Target Indication
    • 11.4.2. Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing
      • 11.4.2.1. Analysis by Geography
      • 11.4.2.2. Analysis by Scale of Operation
      • 11.4.2.3. Analysis by Target Indication
      • 11.4.2.4. Analysis by Type of Primary Packaging
  • 11.5. Demand and Supply Analysis

12. MARKET FORECAST

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions and Forecast Methodology
  • 12.3. Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030
  • 12.4. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product
    • 12.4.1. Ophthalmic API Contract Manufacturing Market, 2020-2030
    • 12.4.2. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030
      • 12.4.2.1. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured
        • 12.4.2.1.1. Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030
        • 12.4.2.1.2. Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030
        • 12.4.2.1.3. Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030
      • 12.4.2.2. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging
        • 12.4.2.2.1. Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030
        • 12.4.2.2.2. Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030
        • 12.4.2.2.3. Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030
        • 12.4.2.2.4. Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030
        • 12.4.2.2.5. Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030
  • 12.5. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication
    • 12.5.1. Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030
    • 12.5.2. Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030
    • 12.5.3. Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030
    • 12.5.4. Ophthalmic Drugs Contract Manufacturing Market for Uveitis, 2020-2030
    • 12.5.5. Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030
  • 12.6. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
    • 12.6.1. Ophthalmic Drugs Contract Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030
    • 12.6.2. Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030
  • 12.7. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Size of Manufacturers
    • 12.7.1. Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030
    • 12.7.2. Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030
    • 12.7.3. Ophthalmic Drugs Contract Manufacturing Market for Large-sized Companies, 2020-2030
  • 12.8. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions
    • 12.8.1. Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030
      • 12.8.1.1. Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030
      • 12.8.1.2. Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030
      • 12.8.1.3. Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-2030
    • 12.8.2. Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030
      • 12.8.2.1. Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030
      • 12.8.2.2. Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030
      • 12.8.2.3. Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030
      • 12.8.2.4. Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030
      • 12.8.2.5. Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030
      • 12.8.2.6. Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030
    • 12.8.3. Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030
      • 12.8.3.1. Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030
      • 12.8.3.2. Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030
      • 12.8.3.3. Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030
      • 12.8.3.4. Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030
      • 12.8.3.5. Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030

13. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE MOLECULE OPHTHALMIC DRUGS / THERAPIES

  • 13.1. Chapter Overview
  • 13.2. Small Molecule Drugs and Biologics
    • 13.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
    • 13.2.2. Comparison of Key Specifications
    • 13.2.3. Comparison of Manufacturing Processes
    • 13.2.4. Comparison of Key Manufacturing-related Challenges

14. SWOT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Comparison of SWOT Factors

15. SURVEY ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Overview of Respondents
    • 15.2.1. Seniority Level of Respondents
  • 15.3. Survey Insights
    • 15.3.1. Type of Product
    • 15.3.2. Type of Primary Packaging
    • 15.3.3. Scale of Operation
    • 15.3.4. Manufacturing Capacity
    • 15.3.5. Location of Manufacturing Facilities
    • 15.3.6. Regulatory Accreditations / Certifications of Manufacturing Facilities
    • 15.3.7. Extent of Outsourcing
    • 15.3.8. Current Market Opportunity

16. EXECUTIVE INSIGHTS

  • 16.1. Chapter Overview
  • 16.2. Selvok Pharmaceutical
    • 16.2.1. Company Snapshot
    • 16.2.2. Interview Transcript: Rahul Gupta, Chief Executive Officer
  • 16.3. Caplin Point Laboratories
    • 16.3.1. Company Snapshot
    • 16.3.2. Interview Transcript: Vivek Partheeban, Chief Operating Officer and Ashok Partheeban, Director, Latin American Operations
  • 16.4. Phytex Australia
    • 16.4.1. Company Snapshot
    • 16.4.2. Interview Transcript: Stuart Smith, Managing Director
  • 16.5. Gland Pharma
    • 16.5.1. Company Snapshot
    • 16.5.2. Interview Transcript: Iranna Bavalatti, General Manager

17. FUTURE GROWTH OPPORTUNITIES

  • 17.1. Chapter Overview
  • 17.2. Integration / Adoption of New and Innovative Technologies
  • 17.3. Capability and Expertise Expansions by CMOs
  • 17.4. Offshoring Outsourcing Activities
  • 17.5. Growing Investments in Existing Infrastructure
  • 17.6. Evolving Client / Sponsor and CMO / CDMO Relationships
  • 17.7. Business Acquisition and Consolidation Activity
  • 17.8. Challenges Faced by Both Sponsors and Service Providers
    • 17.8.1. Concerns Related to Single Use Systems
    • 17.8.2. Concerns Related to Capacity Fluctuations

18. APPENDIX 1: LIST OF OPHTHALMIC MEDICAL DEVICE CONTRACT MANUFACTURERS

19. APPENDIX 2: TABULATED DATA

20 APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

  • Figure 3.1 Estimates on the Visually Impaired Population (US), 2019, 2030 and 2050 (in Millions)
  • Figure 3.2 Classification of Ophthalmic Drug Dosage Forms
  • Figure 3.3 Advantages and Disadvantages of Tablets
  • Figure 3.4 Advantages and Disadvantages of Capsules
  • Figure 3.5 Advantages and Disadvantages of Eye Supplements
  • Figure 3.6 Advantages and Disadvantages of Ointments
  • Figure 3.7 Advantages and Disadvantages of Gels
  • Figure 3.8 Advantages and Disadvantages of Emulsions
  • Figure 3.9 Advantages and Disadvantages of Solutions
  • Figure 3.10 Advantages and Disadvantages of Suspensions
  • Figure 3.11 Advantages and Disadvantages of Sterile Injectables
  • Figure 3.12 Advantages and Disadvantages of Intraocular Inserts
  • Figure 3.13 Common Primary Packaging Formats for Ophthalmic Drugs
  • Figure 3.14 Types of Standalone Contract Service Providers
  • Figure 3.15 Outsourcing in the Ophthalmology Industry
  • Figure 3.16 Commonly Outsourced Operations
  • Figure 3.17 Guidelines for Selecting a CMO Partner
  • Figure 3.18 Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing
  • Figure 4.1 Ophthalmic Drug Contract Manufacturers: Distribution by Year of Establishment
  • Figure 4.2 Ophthalmic Drug Contract Manufacturers: Distribution by Company Size
  • Figure 4.3 Ophthalmic Drug Contract Manufacturers: Distribution by Scale of Operation
  • Figure 4.4 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.5 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.6 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Region-Wise)
  • Figure 4.7 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Country-Wise)
  • Figure 4.8 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Region-Wise)
  • Figure 4.9 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Country-Wise)
  • Figure 4.10 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Product
  • Figure 4.11 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured
  • Figure 4.12 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured and Company Size
  • Figure 4.13 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Primary Packaging
  • Figure 4.14 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Service(s) Offered
  • Figure 4.15 Ophthalmic Drug Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
  • Figure 5.1 Competitiveness Analysis of Ophthalmic API Contract Manufacturers in North America
  • Figure 5.2 Competitiveness Analysis of Ophthalmic API Contract Manufacturers in Europe
  • Figure 5.3 Competitiveness Analysis of Ophthalmic API Contract Manufacturers in Asia-Pacific
  • Figure 5.4 Competitiveness Analysis of Ophthalmic Drug FDF Contract Manufacturers in North America
  • Figure 5.5 Competitiveness Analysis of Ophthalmic Drug FDF Contract Manufacturers in Europe
  • Figure 5.6 Competitiveness Analysis of Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific
  • Figure 6.1 Akorn: Net Revenues, FY 2015-Q3 2019 (USD Million)
  • Figure 6.2 Akorn: Service Portfolio
  • Figure 6.3 Catalent: Net Revenues, FY 2015-FY 2019 (USD Million)
  • Figure 6.4 Catalent: Service Portfolio
  • Figure 6.5 Cayman Chemical: Service Portfolio
  • Figure 6.6 Pillar5 Pharma: Service Portfolio
  • Figure 6.7 Sterling Pharmaceutical Services: Service Portfolio
  • Figure 7.1 FARMIGEA: Service Portfolio
  • Figure 7.2 Lomapharm: Service Portfolio
  • Figure 7.3 Medichem: Service Portfolio
  • Figure 7.4 Recipharm: Net Revenues, FY 2015-Q3 2019 (SEK Million)
  • Figure 7.5 Recipharm: Service Portfolio
  • Figure 7.6 Salvat: Service Portfolio
  • Figure 8.1 Akums: Service Portfolio
  • Figure 8.2 Bal Pharma: Net Revenues, FY 2015-FY 2019 (INR Million)
  • Figure 8.3 Bal Pharma: Service Portfolio
  • Figure 8.4 Entod Pharmaceuticals: Service Portfolio
  • Figure 8.5 Glenmark Pharmaceuticals: Service Portfolio
  • Figure 8.6 Indiana Ophthalmics: Service Portfolio
  • Figure 8.7 Sunways India: Service Portfolio
  • Figure 9.1 Clinical Trials: Distribution by Trial Recruitment Status
  • Figure 9.2 Clinical Trials: Cumulative Distribution by Trial Registration Year, Pre-2010-Q3 2019
  • Figure 9.3 Clinical Trials: Geographical Distribution by Number of Clinical Trials
  • Figure 9.4 Clinical Trials: Percentage Increase in Number of Trials, Pre- and Post-2010
  • Figure 9.5 Clinical Trials: Distribution by Trial Registration Year and Geography, Pre-2010-2018
  • Figure 9.6 Clinical Trials: Geographical Distribution by Enrolled Patient Population
  • Figure 9.7 Clinical Trials: Cumulative Distribution by Enrolled Patient Population and Trial Registration Year, Pre-2010-Q3 2019
  • Figure 9.8 Clinical Trials: Distribution by Phase of Development
  • Figure 9.9 Clinical Trials: Distribution by Trial Recruitment Status and Registration Year, Pre-2010-Q3 2019
  • Figure 9.10 Clinical Trials: Geographical Distribution by Trial Recruitment Status and Registration Year, Pre- and Post-2010
  • Figure 9.11 Clinical Trials: Distribution by Type of Sponsor / Collaborator
  • Figure 9.12 Most Active Industry Players: Distribution by Number of Registered Trials
  • Figure 9.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 9.14 Clinical Trials: Distribution by Type of Intervention
  • Figure 9.15 Clinical Trials: Distribution by Type of Intervention and Trial Registration Year, 2010-2018
  • Figure 9.16 Clinical Trials: Popular Keywords
  • Figure 9.17 Popular Indications: Distribution by Number of Registered Trials
  • Figure 9.18 Clinical Trials: Distribution by Popular Indications and Trial Registration Year, 2010-2018
  • Figure 9.19 Clinical Trials: Distribution by Popular Indications and Type of Trial Sponsor
  • Figure 9.20 Clinical Trials: Distribution by Most Active Industry Players and Trial Registration Year, 2013-2018
  • Figure 9.21 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
  • Figure 10.1 Ophthalmic API Contract Manufacturers: Overall Production Capacity (Million Liters)
  • Figure 10.2 Ophthalmic API Production Capacity: Distribution by Geography (Million Liters)
  • Figure 10.3 Ophthalmic API Production Capacity in North America (Million Liters)
  • Figure 10.4 Ophthalmic API Production Capacity in Europe (Million Liters)
  • Figure 10.5 Ophthalmic API Production Capacity in Asia-Pacific (Million Liters)
  • Figure 10.6 Ophthalmic API Production Capacity: Distribution by Scale of Operation (Million Liters)
  • Figure 10.7 Lab Scale Ophthalmic API Production Capacity (Million Liters)
  • Figure 10.8 Clinical Scale Ophthalmic API Production Capacity (Million Liters)
  • Figure 10.9 Commercial Scale Ophthalmic API Production Capacity (Million Liters)
  • Figure 10.10 Ophthalmic API Production Capacity: Distribution by Company Size (Million Liters)
  • Figure 10.11 Ophthalmic API Production Capacity of Small-sized Companies (Million Liters)
  • Figure 10.12 Ophthalmic API Production Capacity of Mid-sized Companies (Million Liters)
  • Figure 10.13 Ophthalmic API Production Capacity of Large-sized Companies (Million Liters)
  • Figure 10.14 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Liters)
  • Figure 10.15 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Liters)
  • Figure 10.16 Ophthalmic Drug FDF Production Capacity in North America (Million Liters)
  • Figure 10.17 Ophthalmic Drug FDF Production Capacity in Europe (Million Liters)
  • Figure 10.18 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Liters)
  • Figure 10.19 Ophthalmic Drug FDF Production Capacity: Distribution by Scale of Operation (Million Liters)
  • Figure 10.20 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
  • Figure 10.21 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
  • Figure 10.22 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
  • Figure 10.23 Ophthalmic Drug FDF Production Capacity: Distribution by Company Size (Million Liters)
  • Figure 10.24 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Liters)
  • Figure 10.25 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Liters)
  • Figure 10.26 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Liters)
  • Figure 10.27 Ophthalmic Drug FDF Production Capacity: Distribution by Type of Primary Packaging (Million Liters)
  • Figure 10.28 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Liters)
  • Figure 10.29 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Liters)
  • Figure 10.30 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Liters)
  • Figure 10.31 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Units)
  • Figure 10.32 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Units)
  • Figure 10.33 Ophthalmic Drug FDF Production Capacity in North America (Million Units)
  • Figure 10.34 Ophthalmic Drug FDF Production Capacity in Europe (Million Units)
  • Figure 10.35 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Units)
  • Figure 10.36 Ophthalmic Drug FDF Capacity: Distribution by Scale of Operation (Million Units)
  • Figure 10.37 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Units)
  • Figure 10.38 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Units)
  • Figure 10.39 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Units)
  • Figure 10.40 Ophthalmic Drug FDF Capacity: Distribution by Company Size (Million Units)
  • Figure 10.41 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Units)
  • Figure 10.42 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Units)
  • Figure 10.43 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Units)
  • Figure 10.44 Ophthalmic Drug FDF Capacity: Distribution by Type of Primary Packaging (Million Units)
  • Figure 10.45 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Units)
  • Figure 10.46 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Units)
  • Figure 10.47 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Units)
  • Figure 11.1 Overall Commercial Demand for Ophthalmic API Contract Manufacturing (Million Liters)
  • Figure 11.2 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
  • Figure 11.3 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
  • Figure 11.4 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
  • Figure 11.5 Overall Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
  • Figure 11.6 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
  • Figure 11.7 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
  • Figure 11.8 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
  • Figure 11.9 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Type of Primary Packaging (Million Liters)
  • Figure 11.10 Overall Clinical Demand for Ophthalmic API Contract Manufacturing (Million Liters)
  • Figure 11.11 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
  • Figure 11.12 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
  • Figure 11.13 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
  • Figure 11.14 Overall Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
  • Figure 11.15 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
  • Figure 11.16 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
  • Figure 11.17 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
  • Figure 11.18 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Primary Packaging (Million Liters)
  • Figure 11.19 Overall Ophthalmic Drugs Contract Manufacturing: Demand and Supply
  • Figure 12.1 Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030 (USD Billion)
  • Figure 12.2 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product (USD Billion)
  • Figure 12.3 Ophthalmic API Contract Manufacturing Market, 2020-2030 (USD Billion)
  • Figure 12.4 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030 (USD Billion)
  • Figure 12.5 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured (USD Billion)
  • Figure 12.6 Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030 (USD Billion)
  • Figure 12.7 Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030 (USD Billion)
  • Figure 12.8 Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030 (USD Billion)
  • Figure 12.9 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging (USD Billion)
  • Figure 12.10 Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030 (USD Billion)
  • Figure 12.11 Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030 (USD Billion)
  • Figure 12.12 Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030 (USD Billion)
  • Figure 12.13 Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030 (USD Billion)
  • Figure 12.14 Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030 (USD Billion)
  • Figure 12.15 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication (USD Billion)
  • Figure 12.16 Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030 (USD Billion)
  • Figure 12.17 Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030 (USD Billion)
  • Figure 12.18 Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030 (USD Billion)
  • Figure 12.19 Ophthalmic Drugs Contract Manufacturing Market for Uveitis, 2020-2030 (USD Billion)
  • Figure 12.20 Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030 (USD Billion)
  • Figure 12.21 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
  • Figure 12.22 Ophthalmic Drugs Contract Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030 (USD Billion)
  • Figure 12.23 Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Billion)
  • Figure 12.24 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
  • Figure 12.25 Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030 (USD Billion)
  • Figure 12.26 Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Billion)
  • Figure 12.27 Ophthalmic Drugs Contract Manufacturing Market for Large-sized Companies, 2020-2030 (USD Billion)
  • Figure 12.28 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions (USD Billion)
  • Figure 12.29 Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
  • Figure 12.30 Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030 (USD Billion)
  • Figure 12.31 Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030 (USD Billion)
  • Figure 12.32 Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-2030 (USD Billion)
  • Figure 12.33 Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
  • Figure 12.34 Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030 (USD Billion)
  • Figure 12.35 Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030 (USD Billion)
  • Figure 12.36 Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030 (USD Billion)
  • Figure 12.37 Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030 (USD Billion)
  • Figure 12.38 Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030 (USD Billion)
  • Figure 12.39 Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030 (USD Billion)
  • Figure 12.40 Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 12.41 Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030 (USD Billion)
  • Figure 12.42 Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030 (USD Billion)
  • Figure 12.43 Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030 (USD Billion)
  • Figure 12.44 Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030 (USD Billion)
  • Figure 12.45 Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.1 Small Molecule Drugs and Biologics: Historical Trend of FDA Approval, 2010-Q3 2019
  • Figure 13.2 Comparison of Key Characteristics of Small Molecules and Biologics
  • Figure 13.3 Comparison of Manufacturing Processes of Small Molecules and Biologics
  • Figure 14.1 Ophthalmic Drugs Contract Manufacturing: SWOT Analysis
  • Figure 14.2. Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 15.1 Survey Insights: Overview of Respondents
  • Figure 15.2 Survey Insights: Distribution by Type of Organization
  • Figure 15.3 Survey Insights: Distribution by Location of Organization
  • Figure 15.4 Survey Insights: Distribution by Seniority Level
  • Figure 15.5 Survey Insights: Distribution by Type of Product
  • Figure 15.6 Survey Insights: Distribution by Type of Primary Packaging
  • Figure 15.7 Survey Insights: Distribution by Scale of Operation
  • Figure 15.8 Survey Insights: Distribution by Location of Manufacturing Facilities
  • Figure 15.9 Survey Insights: Distribution by Regulatory Accreditations / Certifications of Manufacturing Facilities
  • Figure 15.10 Survey Insights: Distribution by Extent of Outsourcing

List Of Tables

  • Table 4.1 Ophthalmic Drug Contract Manufacturers: List of Industry Players
  • Table 4.2 Ophthalmic Drug Contract Manufacturers: Information on Location of FDF Manufacturing Facilities
  • Table 4.3 Ophthalmic Drug Contract Manufacturers: Information on Location of API Manufacturing Facilities
  • Table 4.4 Ophthalmic Drug Contract Manufacturers: Information on Type of FDF Manufactured and Type of Primary Packaging
  • Table 4.5 Ophthalmic Drug Contract Manufacturers: Information on Type of Service(s) Offered
  • Table 4.6 Ophthalmic Drug Contract Manufacturers: Information on Regulatory Accreditations / Certifications
  • Table 6.1 Akorn: Key Highlights
  • Table 6.2 Akorn: Manufacturing Capabilities
  • Table 6.3 Akorn: Recent Developments and Future Outlook
  • Table 6.4 Catalent: Key Highlights
  • Table 6.5 Catalent: Recent Developments and Future Outlook
  • Table 6.6 Cayman Chemical: Key Highlights
  • Table 6.7 Cayman Chemical: Manufacturing Capabilities
  • Table 6.8 Cayman Chemical: Recent Developments and Future Outlook
  • Table 6.9 Pillar5 Pharma: Key Highlights
  • Table 6.10 Pillar5 Pharma: Recent Developments and Future Outlook
  • Table 6.11 Sterling Pharmaceutical Services: Key Highlights
  • Table 6.12 Sterling Pharmaceutical Services: Recent Developments and Future Outlook
  • Table 7.1 FARMIGEA: Key Highlights
  • Table 7.2 FARMIGEA: Manufacturing Capabilities
  • Table 7.3 FARMIGEA: Recent Developments and Future Outlook
  • Table 7.4 Lomapharm: Key Highlights
  • Table 7.5 Lomapharm: Recent Developments and Future Outlook
  • Table 7.6 Medichem: Key Highlights
  • Table 7.7 Medichem: Manufacturing Capabilities
  • Table 7.8 Medichem: Manufacturing Locations
  • Table 7.9 Medichem: Recent Developments and Future Outlook
  • Table 7.10 Recipharm: Key Highlights
  • Table 7.11 Recipharm: Manufacturing Locations
  • Table 7.12 Recipharm: Recent Developments and Future Outlook
  • Table 7.13 Salvat: Key Highlights
  • Table 7.14 Salvat: Manufacturing Capabilities
  • Table 7.15 Salvat: Recent Developments and Future Outlook
  • Table 8.1 Akums: Key Highlights
  • Table 8.2 Akums: Recent Developments and Future Outlook
  • Table 8.3 Bal Pharma: Key Highlights
  • Table 8.4 Bal Pharma: Recent Developments and Future Outlook
  • Table 8.5 Entod Pharmaceuticals: Key Highlights
  • Table 8.6 Entod Pharmaceuticals: Manufacturing Capabilities
  • Table 8.7 Entod Pharmaceuticals: Recent Developments and Future Outlook
  • Table 8.8 Glenmark Pharmaceuticals: Key Highlights
  • Table 8.9 Glenmark Pharmaceuticals: Recent Developments and Future Outlook
  • Table 8.10 Indiana Ophthalmics: Key Highlights
  • Table 8.11 Indiana Ophthalmics: Recent Developments and Future Outlook
  • Table 8.12 Sunways India: Key Highlights
  • Table 8.13 Sunways India: Recent Developments and Future Outlook
  • Table 10.1 Ophthalmic API Production Capacity (Million Liters): Average Capacity by Geography (Sample Data Set)
  • Table 10.2 Ophthalmic API Production Capacity (Million Liters): Average Capacity by Scale of Operation (Sample Data Set)
  • Table 10.3 Ophthalmic API Production Capacity (Million Liters): Average Capacity by Company Size (Sample Data Set)
  • Table 10.4 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Geography (Sample Data Set)
  • Table 10.5 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Scale of Operation (Sample Data Set)
  • Table 10.6 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Company Size (Sample Data Set)
  • Table 10.7 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Type of Primary Packaging (Sample Data Set)
  • Table 10.8 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Geography (Sample Data Set)
  • Table 10.9 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Scale of Operation (Sample Data Set)
  • Table 10.10 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Company Size (Sample Data Set)
  • Table 10.11 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Type of Primary Packaging (Sample Data Set)
  • Table 13.1 Strengths and Weaknesses of Small Molecules and Biologics
  • Table 13.2 Comparison of Development Characteristics of Small Molecules and Biologics
  • Table 15.1 Survey Insights: Overview of Respondents
  • Table 15.2 Survey Insights: Seniority Level of Respondents
  • Table 15.3 Survey Insights: Type of Product
  • Table 15.4 Survey Insights: Type of Primary Packaging
  • Table 15.5 Survey Insights: Scale of Operation
  • Table 15.6 Survey Insights: Manufacturing Capacity
  • Table 15.7 Survey Insights: Number and Location of Manufacturing Facilities
  • Table 15.8 Survey Insights: Regulatory Accreditations / Certifications of Manufacturing Facilities
  • Table 15.9 Survey Insights: Extent of Outsourcing
  • Table 15.10 Survey Insights: Current Market Opportunity (USD Billion)
  • Table 16.1 Selvok Pharmaceutical: Key Highlights
  • Table 16.2 Caplin Point Laboratories: Key Highlights
  • Table 16.3 Phytex Australia: Key Highlights
  • Table 16.4 Gland Pharma: Key Highlights
  • Table 18.1 Ophthalmic Medical Device Contract Manufacturers: List of Industry Players
  • Table 18.2 Ophthalmic Medical Device Contract Manufacturers: Information on Type of Service(s) Offered and Scale of Operation
  • Table 18.3 Ophthalmic Medical Device Contract Manufacturers: Information on Additional Service(s) Offered
  • Table 18.4 Ophthalmic Medical Device Contract Manufacturers: Information on Location of Manufacturing Facilities
  • Table 18.5 Ophthalmic Medical Device Contract Manufacturers: Information on Device Class and Regulatory Accreditations / Certifications
  • Table 19.1 Estimates on the Visually Impaired Population (US), 2019, 2030 and 2050 (in Millions)
  • Table 19.2 Ophthalmic Drug Contract Manufacturers: Distribution by Year of Establishment
  • Table 19.3 Ophthalmic Drug Contract Manufacturers: Distribution by Company Size
  • Table 19.4 Ophthalmic Drug Contract Manufacturers: Distribution by Scale of Operation
  • Table 19.5 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
  • Table 19.6 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
  • Table 19.7 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Region-Wise)
  • Table 19.8 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Country-Wise)
  • Table 19.9 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Region-Wise)
  • Table 19.10 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Country-Wise)
  • Table 19.11 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Product
  • Table 19.12 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured
  • Table 19.13 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured and Company Size
  • Table 19.14 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Primary Packaging
  • Table 19.15 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Service(s) Offered
  • Table 19.16 Ophthalmic Drug Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
  • Table 19.17 Akorn: Net Revenues, FY 2015-Q3 2019 (USD Million)
  • Table 19.18 Catalent: Net Revenues, FY 2015-FY 2019 (USD Million)
  • Table 19.19 Recipharm: Net Revenues, FY 2015-Q3 2019 (SEK Million)
  • Table 19.20 Bal Pharma: Net Revenues, FY 2015-FY 2019 (INR Million)
  • Table 19.21 Clinical Trials: Distribution by Trial Recruitment Status
  • Table 19.22 Clinical Trials: Cumulative Distribution by Trial Registration Year, Pre-2010-Q3 2019
  • Table 19.23 Clinical Trials: Geographical Distribution by Number of Clinical Trials
  • Table 19.24 Clinical Trials: Percentage Increase in Number of Trials, Pre- and Post-2010
  • Table 19.25 Clinical Trials: Distribution by Trial Registration Year and Geography, Pre-2010-2018
  • Table 19.26 Clinical Trials: Geographical Distribution by Enrolled Patient Population
  • Table 19.27 Clinical Trials: Cumulative Distribution by Enrolled Patient Population and Trial Registration Year, Pre-2010-Q3 2019
  • Table 19.28 Clinical Trials: Distribution by Phase of Development
  • Table 19.29 Clinical Trials: Distribution by Trial Recruitment Status and Registration Year, Pre-2010-Q3 2019
  • Table 19.30 Clinical Trials: Geographical Distribution by Trial Recruitment Status and Registration Year, Pre- and Post-2010
  • Table 19.31 Clinical Trials: Distribution by Type of Sponsor / Collaborator
  • Table 19.32 Most Active Industry Players: Distribution by Number of Registered Trials
  • Table 19.33 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Table 19.34 Clinical Trials: Distribution by Type of Intervention
  • Table 19.35 Clinical Trials: Distribution by Type of Intervention and Trial Registration Year, 2010-2018
  • Table 19.36 Popular Indications: Distribution by Number of Registered Trials
  • Table 19.37 Clinical Trials: Distribution by Popular Indications and Trial Registration Year, 2010-2018
  • Table 19.38 Clinical Trials: Distribution by Popular Indications and Type of Trial Sponsor
  • Table 19.39 Clinical Trials: Distribution by Most Active Industry Players and Trial Registration Year, 2013-2018
  • Table 19.40 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
  • Table 19.41 Ophthalmic API Contract Manufacturers: Overall Production Capacity (Million Liters)
  • Table 19.42 Ophthalmic API Production Capacity: Distribution by Geography (Million Liters)
  • Table 19.43 Ophthalmic API Production Capacity in North America (Million Liters)
  • Table 19.44 Ophthalmic API Production Capacity in Europe (Million Liters)
  • Table 19.45 Ophthalmic API Production Capacity in Asia-Pacific (Million Liters)
  • Table 19.46 Ophthalmic API Production Capacity: Distribution by Scale of Operation (Million Liters)
  • Table 19.47 Lab Scale Ophthalmic API Production Capacity (Million Liters)
  • Table 19.48 Clinical Scale Ophthalmic API Production Capacity (Million Liters)
  • Table 19.49 Commercial Scale Ophthalmic API Production Capacity (Million Liters)
  • Table 19.50 Ophthalmic API Production Capacity: Distribution by Company Size (Million Liters)
  • Table 19.51 Ophthalmic API Production Capacity of Small-sized Companies (Million Liters)
  • Table 19.52 Ophthalmic API Production Capacity of Mid-sized Companies (Million Liters)
  • Table 19.53 Ophthalmic API Production Capacity of Large-sized Companies (Million Liters)
  • Table 19.54 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Liters)
  • Table 19.55 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Liters)
  • Table 19.56 Ophthalmic Drug FDF Production Capacity in North America (Million Liters)
  • Table 19.57 Ophthalmic Drug FDF Production Capacity in Europe (Million Liters)
  • Table 19.58 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Liters)
  • Table 19.59 Ophthalmic Drug FDF Production Capacity: Distribution by Scale of Operation (Million Liters)
  • Table 19.60 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
  • Table 19.61 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
  • Table 19.62 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
  • Table 19.63 Ophthalmic Drug FDF Production Capacity: Distribution by Company Size (Million Liters)
  • Table 19.64 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Liters)
  • Table 19.65 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Liters)
  • Table 19.66 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Liters)
  • Table 19.67 Ophthalmic Drug FDF Production Capacity: Distribution by Type of Primary Packaging (Million Liters)
  • Table 19.68 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Liters)
  • Table 19.69 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Liters)
  • Table 19.70 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Liters)
  • Table 19.71 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Units)
  • Table 19.72 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Units)
  • Table 19.73 Ophthalmic Drug FDF Production Capacity in North America (Million Units)
  • Table 19.74 Ophthalmic Drug FDF Production Capacity in Europe (Million Units)
  • Table 19.75 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Units)
  • Table 19.76 Ophthalmic Drug FDF Capacity: Distribution by Scale of Operation (Million Units)
  • Table 19.77 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Units)
  • Table 19.78 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Units)
  • Table 19.79 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Units)
  • Table 19.80 Ophthalmic Drug FDF Capacity: Distribution by Company Size (Million Units)
  • Table 19.81 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Units)
  • Table 19.82 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Units)
  • Table 19.83 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Units)
  • Table 19.84 Ophthalmic Drug FDF Capacity: Distribution by Type of Primary Packaging (Million Units)
  • Table 19.85 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Units)
  • Table 19.86 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Units)
  • Table 19.87 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Units)
  • Table 19.88 Overall Commercial Demand for Ophthalmic API Contract Manufacturing (Million Liters)
  • Table 19.89 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
  • Table 19.90 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
  • Table 19.91 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
  • Table 19.92 Overall Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
  • Table 19.93 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
  • Table 19.94 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
  • Table 19.95 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
  • Table 19.96 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Type of Primary Packaging (Million Liters)
  • Table 19.97 Overall Clinical Demand for Ophthalmic API Contract Manufacturing (Million Liters)
  • Table 19.98 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
  • Table 19.99 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
  • Table 19.100 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
  • Table 19.101 Overall Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
  • Table 19.102 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
  • Table 19.103 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
  • Table 19.104 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
  • Table 19.105 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Primary Packaging (Million Liters)
  • Table 19.106 Overall Ophthalmic Drugs Contract Manufacturing: Demand and Supply
  • Table 19.107 Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.108 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.109 Ophthalmic API Contract Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.110 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.111 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.112 Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.113 Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.114 Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.115 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.116 Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.117 Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.118 Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.119 Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.120 Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.121 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.122 Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.123 Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.124 Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.125 Ophthalmic Drugs Contract Manufacturing Market for Uveitis, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.126 Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.127 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.128 Ophthalmic Drugs Contract Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.129 Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.130 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Company Size, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.131 Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.132 Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.133 Ophthalmic Drugs Contract Manufacturing Market for Large-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.134 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.135 Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.136 Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.137 Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.138 Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.139 Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.140 Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.141 Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.142 Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.143 Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.144 Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.145 Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.146 Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.147 Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.148 Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.149 Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.150 Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.151 Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 19.152 Small Molecule Drugs and Biologics: Historical Trend of FDA Approval, 2010-Q3 2019
  • Table 19.153 Survey Insights: Distribution by Type of Organization
  • Table 19.154 Survey Insights: Distribution by Location of Organization
  • Table 19.155 Survey Insights: Distribution by Seniority Level
  • Table 19.156 Survey Insights: Distribution by Type of Product
  • Table 19.157 Survey Insights: Distribution by Type of Primary Packaging
  • Table 19.158 Survey Insights: Distribution by Scale of Operation
  • Table 19.159 Survey Insights: Distribution by Location of Manufacturing Facilities
  • Table 19.160 Survey Insights: Distribution by Regulatory Accreditations / Certifications of Manufacturing Facilities
  • Table 19.161 Survey Insights: Distribution by Extent of Outsourcing

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. A. S. Joshi & Company
  • 2. Aarti Industries
  • 3. Abbott Medical Optics
  • 4. AccuMED
  • 5. Actiza Pharmaceutical
  • 6. Admac Formulations
  • 7. Aerie Pharmaceuticals
  • 8. AGC Biologics
  • 9. Aishwarya Lifescience
  • 10. Akorn
  • 11. Akums
  • 12. Alcon
  • 13. Alembic Pharmaceuticals
  • 14. Allergan
  • 15. Amanta Healthcare
  • 16. Ambica Pharma Sales
  • 17. AMETEK Engineered Medical Components
  • 18. Amman Pharmaceutical Industries
  • 19. AMRI
  • 20. ANI Pharmaceuticals
  • 21. Apex Pharmaceuticals
  • 22. Apicore US
  • 23. Arvincare
  • 24. Ashford Pharmaceutical Laboratories
  • 25. Aspen Pharmacare
  • 26. Assiut University
  • 27. Astellas Pharma
  • 28. Aster Pharma
  • 29. AstraZeneca
  • 30. Atrion Medical
  • 31. Aurobindo Pharma
  • 32. Avalign Technologies
  • 33. Axa Parenterals
  • 34. Bachem
  • 35. BAL Pharma
  • 36. Bausch & Lomb
  • 37. Bayer
  • 38. Baylor College of Medicine
  • 39. Beijing Second Pharmaceutical
  • 40. Bennet Pharmaceuticals
  • 41. BePharBel
  • 42. Beximco Pharmaceuticals
  • 43. Binex
  • 44. Biocon
  • 45. Bioglan
  • 46. Biomol
  • 47. Biotech Vision Care
  • 48. Boehringer Ingelheim
  • 49. Bolivac Pharmaceutical
  • 50. Bonarum Pharma
  • 51. Brassica Pharma
  • 52. Bristol-Myers Squibb
  • 53. C&J Industries
  • 54. Cadence
  • 55. Cadila Pharmaceuticals
  • 56. Cairo University
  • 57. Cambrex
  • 58. Caplin Point Laboratories
  • 59. Capsugel
  • 60. Captab Biotec
  • 61. Carclo
  • 62. Catalent
  • 63. Cayman Chemical
  • 64. CCM Pharmaceuticals
  • 65. Centaur Pharmaceuticals
  • 66. Center for Drug Evaluation and Research
  • 67. Century Pharmaceuticals
  • 68. Ceutical Labs
  • 69. Chang Gung Memorial Hospital
  • 70. Charité University
  • 71. ChemCon
  • 72. Chemigran
  • 73. Chifeng Arker Pharmaceutical Technology
  • 74. Chirogate International
  • 75. Chongqing Huapont Pharmaceutical
  • 76. Chromo Laboratories India
  • 77. Ciron Drugs
  • 78. CiVentiChem
  • 79. Coastline International
  • 80. COC Farmaceutici
  • 81. Columbia University
  • 82. Combino Pharm
  • 83. Concord Drugs
  • 84. Consort Medical
  • 85. CooperVision
  • 86. CoreRx
  • 87. CTX Lifesciences
  • 88. Daicel
  • 89. Deepcare Health
  • 90. Delorbis
  • 91. Delpharm
  • 92. Denator
  • 93. Dermopartners
  • 94. Deva Holding
  • 95. DeviceLab
  • 96. Dhruv Life Sciences
  • 97. DM Pharma
  • 98. Doctor Pack
  • 99. Dompé
  • 100. Donatelle
  • 101. Dr. Reddy's Laboratories
  • 102. Duke University
  • 103. Eden Healthcare
  • 104. Edol Laboratory
  • 105. EL Laboratories
  • 106. Eminent Healthcare
  • 107. Emory University
  • 108. Enaltec Labs
  • 109. Entod Pharmaceuticals
  • 110. Eskayef Pharmaceuticals
  • 111. Eurofins
  • 112. Euro-Med Laboratories
  • 113. EVCO Plastics
  • 114. Evergreen Research
  • 115. Evolet Healthcare
  • 116. Excella
  • 117. Excelvision
  • 118. Exela Pharma Science
  • 119. EXODRUG
  • 120. Fabbrica Italiana Sintetici
  • 121. FAMAR
  • 122. Fantabulous Pharma
  • 123. Fareva
  • 124. Farmak
  • 125. Farmastur 2010
  • 126. FARMIGEA
  • 127. FDC
  • 128. Federal University of São Paulo
  • 129. Fermion
  • 130. Finecure Pharmaceuticals
  • 131. FineTech Pharmaceuticals
  • 132. Finnsusp
  • 133. Flagship Biotech International
  • 134. Flamma Group
  • 135. Fleming Laboratories
  • 136. Flexan
  • 137. Forefront Medical Technology
  • 138. Freudenberg Medical
  • 139. FSUE Moscow Endocrine Plant
  • 140. Galentic Pharma
  • 141. Gedeon Richter
  • 142. Genentech
  • 143. Gerresheimer
  • 144. Gland Pharma
  • 145. Glaukos
  • 146. GlaxoSmithKline
  • 147. Glenmark Pharmaceuticals
  • 148. Glochem Industries
  • 149. Golden Drugs
  • 150. Grevis Pharmaceuticals
  • 151. Groupe SYNERLAB
  • 152. Grupo Farmasierra
  • 153. GTIMD
  • 154. Guilin Pharmaceutical
  • 155. Handok
  • 156. Hangzhou Panyu Chemical
  • 157. Hanuchem Laboratories
  • 158. Harmac Medical Products
  • 159. Health Biotech
  • 160. Healthcare Pharmaceuticals
  • 161. Healthy Life Pharma
  • 162. Hemofarm
  • 163. Hetero Drugs
  • 164. Higgs Healthcare
  • 165. Hi-Tech Pharmacal
  • 166. Hospices Civils de Lyon
  • 167. Hovione
  • 168. Hritik Chemicals
  • 169. Hubei Biocause Pharmaceutical
  • 170. Icahn School of Medicine at Mount Sinai
  • 171. IIFA Healthcare
  • 172. Indena
  • 173. Indiana Ophthalmics
  • 174. Indoco Remedies
  • 175. Ind-Swift
  • 176. Instru-med
  • 177. Intas Pharmaceuticals
  • 178. Inteprod
  • 179. Interquim
  • 180. i-Pharmaceuticals
  • 181. I-Tek Medical Technologies
  • 182. ITL Group
  • 183. IVERIC bio
  • 184. J B Chemicals & Pharmaceuticals
  • 185. Jabil
  • 186. Jaeb Center for Health Research
  • 187. Jawa pharmaceuticals
  • 188. JGL
  • 189. Jips Pharmaceuticals
  • 190. Johns Hopkins University
  • 191. Johnson & Johnson Vision Care
  • 192. JSC Tatchempharmpreparaty
  • 193. Jubilant HollisterStier
  • 194. Juniper Pharmaceuticals
  • 195. JunoPacific
  • 196. K C Pharmaceutical
  • 197. Kamat Pharmatech
  • 198. Katsura Chemical
  • 199. Kaysersberg Pharmaceuticals
  • 200. Kemwell
  • 201. Keshava Organics
  • 202. Kilitch Drugs
  • 203. Korten
  • 204. KP Pharmaceutical Technology
  • 205. Krishlar Pharma
  • 206. Kyowa Pharma Chemical
  • 207. Labiana Group
  • 208. Laboratoires Thea
  • 209. Laboratorios Entema
  • 210. Laboratorios Grin
  • 211. Laboratorios Lesvi
  • 212. Laboratorios Sophia
  • 213. Lacrivera
  • 214. Laurus Synthesis
  • 215. Lawson Health Research Institute
  • 216. Lenus LifeCare
  • 217. Lifekyor Pharmaceuticals
  • 218. Lifezen Healthcare
  • 219. Lighthouse Imaging
  • 220. LOBA Feinchemie
  • 221. Logos Pharma
  • 222. Lohmann
  • 223. Lomapharm
  • 224. Lubrizol
  • 225. Maastricht University Medical Center
  • 226. MacFarlan Smith
  • 227. Macter International
  • 228. Mahidol University
  • 229. Makcur Laboratories
  • 230. Martin & Brown Biosciences
  • 231. Massachusetts Eye and Ear Infirmary
  • 232. Massachusetts General Hospital
  • 233. Maxnova Healthcare
  • 234. Maya Biotech
  • 235. Mayo Clinic
  • 236. MD Anderson Cancer Center
  • 237. Medbio
  • 238. MEDFE INDIA
  • 239. Medical University of South Carolina
  • 240. Medical University of Vienna
  • 241. Medichem
  • 242. Medisearch Laboratories
  • 243. Medpharm
  • 244. Memorial Sloan Kettering Cancer Center
  • 245. Mercator Pharmaceutical Solutions
  • 246. Merck
  • 247. Micro Labs
  • 248. Mission Laboratories
  • 249. MMG Healthcare
  • 250. Modern Medical Equipment
  • 251. Moorfields Eye Hospital
  • 252. Morgen Helathcare
  • 253. Mylan
  • 254. Nakoda Chemicals
  • 255. National Cancer Institute
  • 256. National Eye Institute
  • 257. National Heart, Lung, and Blood Institute
  • 258. National Institute of Allergy and Infectious Diseases
  • 259. National Institute of Child Health and Human Development
  • 260. National Institute of Diabetes and Digestive and Kidney Diseases
  • 261. National Institute of Mental Health
  • 262. National Institute of Neurological Disorders and Stroke
  • 263. National Institute on Aging
  • 264. National Institutes of Health
  • 265. National Institutes of Health Clinical Center
  • 266. National Taiwan University Hospital
  • 267. Neiss Labs
  • 268. Nemera
  • 269. NEO Tech Medical
  • 270. Neuland Laboratories
  • 271. NewGen BioPharma
  • 272. Nextar Chempharma Solutions
  • 273. NextPharma
  • 274. Nimbles Biotech
  • 275. Nitin Lifesciences
  • 276. Nitto Medic
  • 277. Nivon Specialities
  • 278. Northwestern University
  • 279. Novartis
  • 280. Nutragen Pharma
  • 281. Nvron Life Science
  • 282. NYU Langone Health
  • 283. Oceanic Pharmachem
  • 284. Ohio State University
  • 285. Olamic Pharma
  • 286. Olon
  • 287. Ora
  • 288. Oregon Health and Science University
  • 289. PannonPharma
  • 290. Park Pharmaceuticals
  • 291. Patheon
  • 292. Perrigo
  • 293. Pfizer
  • 294. Pfizer CentreOne
  • 295. Pharma Stulln
  • 296. Pharmaloop
  • 297. Pharmapack
  • 298. PHARMA-Q
  • 299. Pharmascience
  • 300. Pharmer
  • 301. Phillips-Medisize
  • 302. Phoenix DeVentures
  • 303. Phytex Australia
  • 304. Pillar5 Pharma
  • 305. Piramal Pharma Solutions
  • 306. PMC SMART Solutions
  • 307. Polpharma
  • 308. Polyzen
  • 309. PrimaPharma
  • 310. Prisha Healthcare
  • 311. Procos
  • 312. Product Resources
  • 313. ProMed Pharma
  • 314. Proton Pharma
  • 315. Pushkar Pharma
  • 316. Qilu Pharmaceutical
  • 317. Qualiphar-Gifrer
  • 318. Qualitron Bio Medica
  • 319. Quality Tech Services
  • 320. Qualtra Pharmaceuticals
  • 321. Radico Remedies
  • 322. RAFARM
  • 323. Recipharm
  • 324. Red Star Contract Manufacturing
  • 325. REDWING Pharma
  • 326. Regeneron Pharmaceuticals
  • 327. Remington Pharmaceuticals
  • 328. Ritedose
  • 329. Riverside Medical Packaging
  • 330. Roche
  • 331. Röchling Medical
  • 332. Rohto Pharmaceuticals
  • 333. Rompharm
  • 334. Rubicon Research
  • 335. Rusan Pharma
  • 336. Salvat
  • 337. Salvus Pharma
  • 338. Samsung Medical Center
  • 339. Sanbio
  • 340. SANOCHEMIA Pharmazeutika
  • 341. Sanofi
  • 342. Santen
  • 343. Saphnix Lifesciences
  • 344. Saraca Solutions
  • 345. Sarvodaya Drugs & Pharmaceuticals
  • 346. SCD Pharmaceuticals
  • 347. ScinoPharm Taiwan
  • 348. Second Source Medical
  • 349. Selvok Pharmaceutical
  • 350. Sensimed
  • 351. Sentiss Pharma
  • 352. Seoul National University Hospital
  • 353. Shahid Beheshti University of Medical Sciences
  • 354. Shandong Xinhua Pharmaceutical
  • 355. Sheba Medical Center
  • 356. Shenzhen Haorui Industrial
  • 357. Shilpa Medicare
  • 358. Shire
  • 359. SHL Group
  • 360. Siegfried
  • 361. Singapore National Eye Centre
  • 362. Sinphar Pharmaceutical
  • 363. Sion Healthcare
  • 364. Smruthi Organics
  • 365. Societa Italiana Medicinali Scandicci
  • 366. Sofarimex
  • 367. Softigel
  • 368. Solitaire Pharmacia
  • 369. SOVEREIGN PHARMA
  • 370. Sovrin Plastics
  • 371. Spark Therapeutics
  • 372. Sparton
  • 373. Spectrum Plastics Group
  • 374. Square Pharmaceuticals
  • 375. Sricure Herbs
  • 376. SRS Pharmaceutical
  • 377. Stanford University
  • 378. StarFish Medical
  • 379. Stellartech
  • 380. Sterling Pharmaceutical Services
  • 381. Stevanato Group
  • 382. Strategix Medical Solutions
  • 383. Sun Yat-sen University
  • 384. Sungwoo Life Sciences
  • 385. Sunways
  • 386. Swiss Pharma
  • 387. Symed Labs
  • 388. Syncom Healthcare
  • 389. Systochem Laboratories
  • 390. Tahira Industries
  • 391. Taj Pharmaceuticals
  • 392. Takeda
  • 393. Tara Innovations
  • 394. Tegra Medical
  • 395. Teika Pharmaceutical
  • 396. Teligent
  • 397. Texas Therapeutics
  • 398. The Cleveland Clinic
  • 399. The Hong Kong Polytechnic University
  • 400. Titan Pharma
  • 401. Tonus-Les
  • 402. Torrent Pharmaceuticals
  • 403. Trelleborg Sealing Solutions
  • 404. Trumac Healthcare
  • 405. Unichem Laboratories
  • 406. Uni-Med India
  • 407. Union Quimico Farmacéutica
  • 408. Unison Pharmaceuticals
  • 409. University Health Network, Toronto
  • 410. University Hospital Center of Bordeaux
  • 411. University of Alabama at Birmingham
  • 412. University of British Columbia
  • 413. University of California, Davis
  • 414. University of California, Los Angeles
  • 415. University of California, San Diego
  • 416. University of California, San Francisco
  • 417. University of Chicago
  • 418. University of Colorado, Denver
  • 419. University of Iowa
  • 420. University of Miami
  • 421. University of Michigan
  • 422. University of North Carolina, Chapel Hill
  • 423. University of Oxford
  • 424. University of Pittsburgh
  • 425. University of Rochester
  • 426. University of São Paulo
  • 427. University of Utah
  • 428. University of Waterloo
  • 429. University of Wisconsin, Madison
  • 430. University of Zurich
  • 431. URSAPHARM Arzneimittel
  • 432. USV
  • 433. Valentis Pharma
  • 434. Valtronic
  • 435. VDASP Pharmaceuticals
  • 436. Vergo Pharma Research Laboratories
  • 437. VersaPharm
  • 438. Vetter Pharma
  • 439. Viant Medical
  • 440. Vibcare
  • 441. Vienna Institute for Research in Ocular Surgery
  • 442. Vivimed
  • 443. VxP Pharma
  • 444. Wanbury
  • 445. Wannock pharmaceuticals
  • 446. Washington University School of Medicine
  • 447. Wenzhou Medical University
  • 448. Wills Eye Hospital
  • 449. Wintac
  • 450. Wockhardt
  • 451. Wuhu Sanyi Xincheng Pharmaceutical
  • 452. WuXi AppTec
  • 453. Xellia Pharmaceuticals
  • 454. Y S Lab
  • 455. Yale University
  • 456. YaoPharma
  • 457. Yonsei University
  • 458. Zenius
  • 459. Zenlabs
  • 460. Zylig Lifesciences